Table 1. Baseline sociodemographic and clinical characteristics of the sample including FEP patients (n=36) and controls (n=19).
| Control | Case, baseline | Case, 2 months | Case, 1 year | |
|---|---|---|---|---|
| Age | 27 (23.7, 33.8) | 24.5 (22, 29.5) | 23.4 (21.7, 29.7) | 26.7 (22.6, 33.4) |
| Brief Psychiatric Rating | 24 (24, 25) | 46 (39.5, 55) | 36.5 (31.8, 43.2) | 30.5 (25, 40.8) |
| Global assessment of functioning | 90 (85, 90) | 32 (30, 37.2) | 38 (34.8, 40) | 40 (37.2, 52.5) |
| Height | 174 (168, 179) | 175 (167, 183) | 173 (166, 184) | 172 (164, 181) |
| Male | 10/19 (53%) | 20/36 (56%) | 11/24 (46%) | 4/12 (33%) |
| Plasma glucose | 4.2 (3.85, 4.42) | 4.16 (3.84, 4.58) | 4.2 (3.99, 4.41) | 4.14 (4.06, 4.24) |
| Olazapine | — | 12/36 (33%) | 5/24 (21%) | 3/12 (25%) |
| Risperidone | — | 10/36 (28%) | 5/24 (21%) | 3/12 (25%) |
| Serum C-peptide | 458 (367, 596) | 553 (434, 868) | 570 (433, 722) | 544 (315, 720) |
| Serum HDL cholesterol | 1.38 (1.34, 1.64) | 1.37 (1.13, 1.54) | 1.29 (1.15, 1.61) | 1.22 (1.11, 1.67) |
| Serum LDL cholesterol | 2.5 (2.11, 3.22) | 2.86 (2.4, 3.5) | 2.95 (2.43, 3.04) | 2.64 (2.26, 3.3) |
| Serum insulin | 7 (4.4, 9.35) | 8.55 (6.15, 13.2) | 8.35 (7.1, 14.2) | 11.3 (8.15, 13.8) |
| Serum lipoprotein A-I | 1.46 (1.37, 1.76) | 1.42 (1.25, 1.52) | 1.38 (1.23, 1.64) | 1.37 (1.23, 1.68) |
| Serum lipoprotein B | 0.69 (0.565, 0.86) | 0.825 (0.66, 0.96) | 0.815 (0.715, 0.935) | 0.8 (0.61, 0.89) |
| Serum total cholesterol | 4.58 (3.92, 5.6) | 4.59 (4.21, 5.55) | 4.79 (4.27, 5.34) | 4.81 (4.15, 5.28) |
| Serum triglycerides | 0.85 (0.71, 1.1) | 1.1 (0.765, 1.37) | 1.23 (0.792, 1.72) | 0.98 (0.685, 1.94) |
| Waist | 81 (76.5, 91) | 83 (79, 89.2) | 88.5 (82, 96.5) | 91 (86.5, 97) |
| Weight | 72.9 (63.1, 79.6) | 69.7 (62, 79.1) | 76 (60, 84.3) | 74 (68, 95.8) |
Abbreviations: FEP, first-episode psychosis; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Data shown as n (%), or median (25%, 75% quartiles).